Wedbush downgraded Astria Therapeutics (ATXS) to Neutral from Outperform with a price target of $13, down from $28, after the company reached an agreement to be acquired by BioCryst (BCRX) for cash and stock at an implied value of $13 per share, or $700M.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ATXS:
- BioCryst price target raised to $27 from $17 at Citizens JMP
- Astria downgraded to Market Perform from Outperform at Citizens JMP
- BioCryst reinstated with a Buy at TD Cowen
- Astria Therapeutics downgraded to Perform from Outperform at Oppenheimer
- BioCryst weakness presents ‘compelling’ buying opportunity, says RBC